



**Cancer Research UK
Clinical Research Monitoring Panel (CRMP)**

Supplementary Terms of Reference

This document sets out the key responsibilities that the Scientific Executive Board (**SEB**) has delegated to the Clinical Research Monitoring Panel (**CRMP** or the **Panel**). It should be read in conjunction with the [General Terms of Reference for Funding Committees](#).

Note that although the CRMP is referred to as a 'panel', it has the powers and responsibilities of a Cancer Research UK Funding Committee, subject to its Terms of Reference.

1. Remit:

- 1.1. To review and, subject to para 1.21.1, make funding decisions in relation to scientific milestone reports for Cancer Research UK's clinical research grants, noting that the Clinical Research Committee (rather than the CRMP) has overall responsibility for maintain strategic oversight of Cancer Research UK's clinical research portfolio.
- 1.2. Where the Panel believes funding for a grant within the Clinical Research Committee portfolio should be withdrawn, to make that recommendation and refer the report to the Clinical Research Committee for final decision.

2. Membership:

- 2.1. The Panel will comply with the membership requirements set out in [the General Terms of Reference for Funding Committees](#).
- 2.2. Additional external members may be co-opted to ensure that the Panel has expertise in areas pertinent to academic cancer clinical trial research, including surgery, medical and clinical oncology, pathology, medical statistics, and clinical trials.

3. Meetings:

- 3.1. The Panel will meet in accordance with the [General Terms of Reference for Funding Committees](#). In general, it will meet twice a year.
- 3.2. If invited by the SEB, the Chair of the Panel will attend an SEB meeting on an annual basis to ensure that the Panel is aligned with the strategic priorities of Cancer Research UK.

4. Document information:

| | |
|----------------------------|--|
| Version | 1 |
| Approved by | Scientific Executive Board |
| Approval Date | April 2017 |
| Next scheduled review date | December 2019 |
| Document owner | Research Funding Operations Team (R&I) |